TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$135.32M

FY 2025 · Annual

Investing Cash Flow

$109.37M

FY 2025 · Annual

Financing Cash Flow

-$336,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Depreciation & Amortization3.33M5.14M5.36M4.11M2.87M
Deferred Income Tax(9.16M)0000
Stock-Based Compensation2.52M4.55M5.21M9.55M11.71M
Change in Working Capital(5.9M)(10.23M)17.61M5.05M(18.18M)
Accounts Receivables00000
Inventory00000
Accounts Payables10K528K(52K)1.99M(3.01M)
Other Working Capital(5.91M)(10.76M)17.66M3.06M(15.17M)
Other Non-Cash Items9.16M260K(315K)(2.03M)(1.95M)
Operating Cash Flow(48.68M)(66.5M)(61.36M)(110.82M)(135.32M)
Capital Expenditures(9.94M)(4.23M)(3.15M)(3.83M)(4.41M)
Acquisitions (Net)00000
Purchases of Investments00(77.61M)(241.45M)(87.47M)
Sales of Investments0020M192.66M201.25M
Other Investing Activities00000
Investing Cash Flow(9.94M)(4.23M)(60.76M)(52.61M)109.37M
Debt Repayment029.35M015.31M0
Common Stock Issued89.65M193K42.41M33.13M264K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities291K(191K)93.03M160.32M(600K)
Financing Cash Flow189.67M29.36M135.44M208.77M(336K)
Effect of Forex Changes00000
Net Change in Cash131.05M(41.37M)13.33M45.33M(26.28M)
Free Cash Flow(58.62M)(70.73M)(64.5M)(114.65M)(139.73M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$129.8M
+ D&A$2.9M
+ Stock-Based Comp$11.7M
+ Deferred Tax$0
- Working Capital-$18.2M
- Other Non-Cash-$1.9M
= Operating Cash Flow-$135.3M
- Capex-$4.4M
= Free Cash Flow-$139.7M

Analysis

FY2025 free cash flow is -$139.7M. FCF conversion is 107.7% of net income. Operating cash flow was -$135.3M, with capex of -$4.4M. The largest bridge item is Working Capital at -$18.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportJun 22, 2026
4Statement of changes in beneficial ownershipMay 22, 2026
4Statement of changes in beneficial ownershipMay 22, 2026
4Statement of changes in beneficial ownershipMay 22, 2026
8-KCurrent reportMay 22, 2026

Does TCRX generate free cash flow?

TScan Therapeutics, Inc. (TCRX) generated -$139.73M of free cash flow in fiscal 2025.

How much operating cash flow does TCRX produce?

Operating cash flow was -$135.32M, before capital expenditures of $4.41M.